Cached score snapshot

US.CRL · Charles River Laboratories

110分制 57.9/110；5D動能v2 15/50；排序分 72.9/160

Back to ranking Open volume snapshot

Ranking score 72.9/160

Main score 57.9/110

5D momentum v2 15/50

Rank #138

Setup grade B 69

Score breakdown

觀望

Elevated twelvedata

Score and price trend

B 69 Money flow A · Technical A · lift 1.38x

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

**Historical projection**
Model	Median	P25/P75	歷史相似情境上漲比例	Down5	Actual / compare
Rolling DOE best · score 2.454 · anchors 120	+1.46%	-1.19% / +5.57%	57.5%	2.5%	Actual +9.48% · vs median +8.02% · inside 25-75 band
30D observation	+2.18%	-6.37% / +7.16%	65%	27.5%	Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160	+0.80%	-1.06% / +2.95%	60.6%	3.8%	Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-07-28 → 2026-12-01 · 119 archived points · 1 Improving turn signal · 5 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 72.9

Display grade 觀望

Model version cursor_18_27_news_v2_160

Main score 57.9/110 (觀望)

5D momentum v2 15/50 (弱)

Score with momentum v2 72.9/160 (低排序)

Risk level Elevated

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60

ma20 298.3875

ma50 290.299

close 315.45

prevClose 300.02

avgVolume20 979656

volumeRatio 1.3

changePercent 5.14

Metrics snapshot

close 315.45

volume 1272223

changePercent 5.14

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 57.9/110

Main rating 觀望

5D momentum v2 15/50

Score with momentum v2 72.9/160

Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 1.5/5 · 較差

Dimension score 1.5/5

Dimension grade 較差

Sub-items

pbPoints 0.2

pePoints 0

epsPoints 0

roePoints 0

debtPoints 0.4

marginPoints 0

turnoverUsdM 401.3228

volumePoints 0.5

revenuePoints 0

dividendPoints 0

marketCapPoints 0.4

資金流 — 14.8/20 · 良好

Dimension score 14.8/20

Dimension grade 良好

Sub-items

cmfPoints 2.4

mfiPoints 2.4

obvPoints 4

vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL

symbol US.CRL

message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.

optional true

holderCount n/a

holderPoints 2

top10ShareRatio n/a

concentrationPenalty 0

institutionPoints 2

市場環境 — 6.4/15 · 較差

Dimension score 6.4/15

Dimension grade 較差

Sub-items

vix

score 1.8

details

source twelvedata+fred

vixClose 18.44

trend

score 1.8

details

qqq

ma20 739.872

ma50 726.6152

name QQQ

close 717.63

points 0.4

spy

ma20 770.6165

ma50 768.2866

name SPY

close 769.05

points 1.4

source twelvedata+fred

atrPct 4.1776

atrPoints 2

cciPoints 0.8

vixPoints 1.8

marketTrendPoints 1.8

催化劑 — 2/20 · 較差

Dimension score 2/20

Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model

articleCount 8

catalystCount 0

catalystPoints 2

風險管理 — 6.3/10 · 一般

Dimension score 6.3/10

Dimension grade 一般

Sub-items

position

score 1.3

details

atrPct 4.1776

turnoverUsdM 401.3228

liquidityPoints 0.6

volatilityPoints 0.7

rrPoints 1.8

stopLevels

symbol US.CRL

rr_range 1:1.0-1:2.5

risk_profile 中等

stop_loss_price 289.0936

strength_details

ma_score 1.5

atr_score 1

rsi_score 3

macd_score 3

volume_score 2

market_adjustment 1

risk_reward_ratio 1.6

stop_loss_percent 8.4

take_profit_price 357.9717

target_multiplier 2.2

technical_strength 2.2

take_profit_percent 13.5

positionPoints 1.3

stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used

sector Health Care

concentratedSectorPenalty 0

riskRewardRatio 1.6158

stopLossPercent 8.3552

diversificationPoints 2

技術信號 — 22.9/30 · 良好

Dimension score 22.9/30

Dimension grade 良好

Sub-items

bbPoints 3

adxPoints 3

sarPoints 1.2

vcpPoints 2.2

macdPoints 4

vcpPayload

vcp_pass false

vcp_score 2.2

vcp_reason 波幅收縮(20.9%→14.2%)；跌縮量(近10日3日)；站上MA50；Ready=Y；Confirm=N

vcp_metrics

up_days 4

vol_ref 971203.3333

down_days 5

vcp_ready true

above_ma50 true

avg_vol_10 937000

avg_vol_20 972900

avg_vol_30 971203.3333

range_pct_10 0.1422

range_pct_20 0.1796

range_pct_30 0.2093

up_expand_ok false

lookback_used 59

near_20d_high true

contraction_ok true

down_shrink_ok true

up_expand_days 0

breakout_20d_ok false

vol_ratio_10_30 0.9648

dist_to_20d_high 0.0536

down_shrink_days 3

breakout_level_20d 333.3

vcp_breakout_confirm false

contraction_ratio_10_30 0.6795

vcp_name_en Volatility Contraction Pattern

vcp_name_zh 波動收縮形態

vol_contraction true

kdjAdxPoints 0.7

rsiKdjPoints 4

volumeWeight 2

maCrossPoints 1.6

shortRsiPoints 1

shortMacdPoints 0.4

volConfirmPoints 0.6

volumePointsTechnical 1.2

情緒分析 — 4/10 · 較差

Dimension score 4/10

Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model

articleCount 8

negativeHits 0

positiveHits 2

sentimentScoreRaw 0.6

sentimentData

raw {"id":142948227,"url":"https://finnhub.io/api/news?id=79f0a13d734af94e39735179cc832b22a1bdfab53f0be68fd4b4623bb8fef809","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.","category":"company","datetime":1792163259,"headline":"Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers"}, {"id":142697487,"url":"https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"PGNY vs. CRL: Which Stock Is the Better Value Option?","category":"company","datetime":1791384004,"headline":"PGNY or CRL: Which Is the Better Value Stock Right Now?"}, {"id":142592897,"url":"https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...","category":"company","datetime":1790967988,"headline":"Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"}, {"id":142499581,"url":"https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]","category":"company","datetime":1790698275,"headline":"Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"}, {"id":142402006,"url":"https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...","category":"company","datetime":1790316582,"headline":"Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"}, {"id":142387947,"url":"https://finnhub.io/api/news?id=47b738c3783bc88c4221394848f31db0a9c7fff9a26d3d04bcfb555d444675b6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.","category":"company","datetime":1790291098,"headline":"Why Charles River Laboratories (CRL) Stock Is Up Today"}, {"id":142385395,"url":"https://finnhub.io/api/news?id=6f5b2fba693b22fa73e8e6a1e1077de6b506ff84c3e4f65e588abdc05bf56df2","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"CRL","summary":"Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day September 24, 2026 9:00 AM EDTCompany ParticipantsTodd Spencer - Corporate Vice...","category":"company","datetime":1790263799,"headline":"Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript"}, {"id":142379184,"url":"https://finnhub.io/api/news?id=c9c3fd21de2cd9847355174c946ed9a05e8fef2bcfe94440baa4e75ebe390b60","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"CRL","summary":"2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.","category":"company","datetime":1790242663,"headline":"Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow"}

raw_source {"id":143031687,"url":"https://finnhub.io/api/news?id=9767c866ea027121f6e583a1c9d55c71caf1930dcf32f3011cf51a1089f09880","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"S&P 500 top movers today: Equifax and Hasbro gained over 10%, while General Motors and DaVita fell more than 7% in a mixed session.","category":"company","datetime":1792523164,"headline":"S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall"}, {"id":143032118,"url":"https://finnhub.io/api/news?id=5706a549de19317028a89a3d0711c22462e81539f7468dfc667f38a79817cba4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"The S&P 500 Health Care Sector was on track to set a fresh closing high, leading Tuesday's broad market gains.","category":"company","datetime":1792521676,"headline":"The Healthcare Sector Nears a New High. These Stocks Are Leading the Charge."}, {"id":143031680,"url":"https://finnhub.io/api/news?id=e11728fc8f5fa19627c71da56097d365124708caa38ac808ec39585063e67696","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"S&P 500 top movers for today's US session: Equifax led gainers at 11.46%, while General Motors led losers at -7.72%, ranked by percentage change.","category":"company","datetime":1792514161,"headline":"S&P 500 Top Movers: Gainers and Losers From Today's US Session"}, {"id":143003297,"url":"https://finnhub.io/api/news?id=f1acfd41fd9b527a19736eca9f01d8234fd7f6f03163c95fadf8b26091f93997","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"The global clinical trial management services market is projected to grow from $36.2 billion in 2025 to $68.4 billion by 2033, a new Research and Markets report finds, with North America holding 34.7%; high service costs and strict regulation remain hurdles for IQVIA, ICON, Medpace and Charles River Laboratories.Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- \"Clinical Trial Management Services Market Size, Share & Trends Analysis Report 2026-2033\" has been added to ResearchAndMarkets.com's offering.","category":"company","datetime":1792404180,"headline":"Clinical Trial Management Services Market Size, Share, Trends, and Forecast, 2026-2033 | Drugmakers' Outsourcing Push Lifts Clinical Trial Management Toward $68 Billion"}, {"id":142948227,"url":"https://finnhub.io/api/news?id=79f0a13d734af94e39735179cc832b22a1bdfab53f0be68fd4b4623bb8fef809","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.","category":"company","datetime":1792163259,"headline":"Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers"}, {"id":142944401,"url":"https://finnhub.io/api/news?id=5421d801a102802a5e484c0529471ffad3f61138737e42180b93aaa13d80796c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Moby summary of State Street Corporation's Q3 2026 earnings call","category":"company","datetime":1792067400,"headline":"State Street Corporation Q3 2026 Earnings Call Summary"}, {"id":142918192,"url":"https://finnhub.io/api/news?id=ae660821716f3ea046ae6c39fc8c801e40c2138288b6e40e46dd199a41500235","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Charles River (NYSE:CRL) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.15%. Currently, Charles River has a market capitalization of $15.44","category":"company","datetime":1791978333,"headline":"Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Years"}, {"id":142881848,"url":"https://finnhub.io/api/news?id=d92b840d57c7cf26fe9122c59c96eb5effa81ac8761ad4ac4bb9f698ce01fff4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"The partnership focuses on biologics quality control as well as viral and release testing under cGMP standards.","category":"company","datetime":1791973542,"headline":"Charles River partners with Magellan Stem Cells on cell therapy"}, {"id":142872378,"url":"https://finnhub.io/api/news?id=62738761f42c073d33babe49d64f521c4f661034a6934bafccd6cd78abbca7c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Outsource clinical trials and leverage AI, decentralized models and regulatory expertise to cut costs, accelerate drug development and expand patient access.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- \"Healthcare Contract Research Organization (CRO) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. Global Healthcare Contract Research Organization (CRO) Market to Reach US$63.3 Billion by 2032 The global Healthcare Contract Research Organization (CRO) market, e","category":"company","datetime":1791965460,"headline":"Healthcare Contract Research Organization (CRO) - Global Strategic Business Report: Secure Share of US$63.3 Billion Market by 2032 as IQVIA, ICON, Charles River, and Syneos Health Accelerate AI Trials"}, {"id":142882861,"url":"https://finnhub.io/api/news?id=93c15420dba820f73acdaf92c76e738f90d3f27ffc0b3533e13299a950b32e2a","image":"","source":"Benzinga","related":"CRL","summary":"Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.","category":"company","datetime":1791894279,"headline":"Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340"}, {"id":142847677,"url":"https://finnhub.io/api/news?id=cddde621353a46d82cf197be60342f9be17dd2d28c88a4b6ef3b00fae32ed5d7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., October 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r","category":"company","datetime":1791892800,"headline":"Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development"}, {"id":142849184,"url":"https://finnhub.io/api/news?id=cae78aa67d83366e974f3475b844be12c4846a61277b95a025a3a90fd39e09b6","image":"","source":"Benzinga","related":"CRL","summary":"Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical","category":"company","datetime":1791878667,"headline":"Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions"}, {"id":142821923,"url":"https://finnhub.io/api/news?id=53efda3451be265502610e54f2aac7d0c18c98fe0810a2e8a51f996620eccbf2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.","category":"company","datetime":1791816423,"headline":"1 S&P 500 Stock to Target This Week and 2 We Question"}, {"id":142820380,"url":"https://finnhub.io/api/news?id=423149643bbad89b0db5f5911a4cddf6c995655e87d48181f8346bb1364ce1df","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Boost ROI with AI-led design, automated high-throughput screening, customizable libraries, local production and diversified sourcing to cut costs and speed development.Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- \"Synthetic Antibody Library Global Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global synthetic antibody library market is experiencing rapid expansion, supported by rising demand for therapeutic antibodies, continued growth in biopharmaceutical research an","category":"company","datetime":1791813600,"headline":"Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera"}, {"id":142760739,"url":"https://finnhub.io/api/news?id=9c7afb02e7e9d7abcc03d3cb0a983871d3e7356993eb8a452fb378da3b71b958","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., October 09, 2026--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call","category":"company","datetime":1791547200,"headline":"Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call"}, {"id":142730419,"url":"https://finnhub.io/api/news?id=5741fde32d2d428cfb091510e2b9dc970e9a9cdc9798a0a9de13df26fb600389","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.","category":"company","datetime":1791477301,"headline":"Stay informed with the top movers within the S&P500 index on Thursday."}, {"id":142697487,"url":"https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"PGNY vs. CRL: Which Stock Is the Better Value Option?","category":"company","datetime":1791384004,"headline":"PGNY or CRL: Which Is the Better Value Stock Right Now?"}, {"id":142695289,"url":"https://finnhub.io/api/news?id=6a5ab641dfa540f4273e0bc7343b63546d8bed6db48b9a05cc96fc59a2885f95","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.","category":"company","datetime":1791377460,"headline":"Charles River Gains 75.8% in a Year: What's Driving the Rally?"}, {"id":142665917,"url":"https://finnhub.io/api/news?id=96f2244ba53353df9f32cdb272b02c1bd237949d5c8d05b5b004c1bb61985f59","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.","category":"company","datetime":1791296940,"headline":"Is It Prudent to Add Teleflex Stock to Your Portfolio Now?"}, {"id":142663488,"url":"https://finnhub.io/api/news?id=442468620f7300edd97e96030827e9ed4020cc52e307d09ca48212ba3f770b1d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass. & LONDON, October 06, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches","category":"company","datetime":1791288000,"headline":"Charles River and Autolomous Partner to Transform Laboratory Execution Systems"}, {"id":142664252,"url":"https://finnhub.io/api/news?id=848f97ea160777aeb7ed35e35b75b28220a8868d46bf0b3145004ec3da03062c","image":"","source":"Benzinga","related":"CRL","summary":"Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the launch of Apollo","category":"company","datetime":1791274390,"headline":"Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration"}, {"id":142638288,"url":"https://finnhub.io/api/news?id=4796f000e83db0803c6b2ad30c002a2fc93fd2d01cc72622994706b14f78ea94","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.","category":"company","datetime":1791227101,"headline":"Uncover the latest developments among S&P500 stocks in today's session."}, {"id":142637485,"url":"https://finnhub.io/api/news?id=67961b010b1f3caecc8f221b133dc532a01b4d12e570aa9d8e37f37167ccb5a0","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.","category":"company","datetime":1791218101,"headline":"Which S&P500 stocks are moving on Monday?"}, {"id":142592897,"url":"https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...","category":"company","datetime":1790967988,"headline":"Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"}, {"id":142577515,"url":"https://finnhub.io/api/news?id=4004dabfc4e71581127dd887539a0ecf3abbbdbfca0c74f5d1873ab9ad91f51b","image":"","source":"Fintel","related":"CRL","summary":"","category":"company","datetime":1790925229,"headline":"Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39"}, {"id":142518422,"url":"https://finnhub.io/api/news?id=4f000e219b76905d0e4602a2357c480f40a8a0d43c3dffe4cc108d40fa5b5d11","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- \"Animal Model - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp","category":"company","datetime":1790774880,"headline":"Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory"}, {"id":142517531,"url":"https://finnhub.io/api/news?id=4bd4d48cb235fd301171991d0bfe3cb1a9387d7e335c5a84377e0aab6d16e21c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Here is how Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.","category":"company","datetime":1790772002,"headline":"Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?"}, {"id":142520420,"url":"https://finnhub.io/api/news?id=3bcdfc31b28a1e9d32bf937b1007a9d54474bac7dbab9269b99cd19feddf03cc","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market capitalization of $15.15","category":"company","datetime":1790766039,"headline":"Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today"}, {"id":142520421,"url":"https://finnhub.io/api/news?id=cc0cb7255ec4f1bd0a5564f8462ab5a34a8f861a00590f3143b8ce54803c43bd","image":"","source":"Benzinga","related":"CRL","summary":"UBS analyst Kevin Caliendo reinstates Charles River (NYSE:CRL) with a Buy and announces $357 price target.","category":"company","datetime":1790757739,"headline":"UBS Reinstates Buy on Charles River, Announces $357 Price Target"}, {"id":142499581,"url":"https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]","category":"company","datetime":1790698275,"headline":"Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"}, {"id":142498448,"url":"https://finnhub.io/api/news?id=33d389ce10e1c3a470a93edeb6350bbdab2e11354e2d65d66fcec4c7016e4514","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to","category":"company","datetime":1790697120,"headline":"Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River"}, {"id":142498449,"url":"https://finnhub.io/api/news?id=b4e488f22dcd680cd9d6f1073f1177520302265edfe111909503cd1374c8c6fb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Computer-Aided Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound","category":"company","datetime":1790697060,"headline":"Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth."}, {"id":142495085,"url":"https://finnhub.io/api/news?id=1f13747f30781afd5effdb4cfed035abc4e598b4fd9cf0d20bc8009c926b865a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:","category":"company","datetime":1790681580,"headline":"NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs"}, {"id":142487027,"url":"https://finnhub.io/api/news?id=23e5453460dd9e1f12da1cd9842974b512e65d80948df3cb7bb3f7e48175af39","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Boost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Experimental Animal Model Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experimental Animal Model Market, which is projected to reach USD 1.31 billion in 2026 and expand at a comp","category":"company","datetime":1790669220,"headline":"Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, The Jackson Laboratory, Taconic Biosciences and Crown Bioscience Profiled"}, {"id":142467316,"url":"https://finnhub.io/api/news?id=da8b2e74678b76f253471de9bda93f56ad89236250cb85d9012c72196928a9af","image":"","source":"Benzinga","related":"CRL","summary":"Jefferies analyst David Windley maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.","category":"company","datetime":1790589930,"headline":"Jefferies Maintains Buy on Charles River, Raises Price Target to $340"}, {"id":142452869,"url":"https://finnhub.io/api/news?id=da87991122131ba1bc51d2b82e98e0e933eff651c52951f9b03cee7151f06fa8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook.","category":"company","datetime":1790542514,"headline":"Is Charles River Laboratories Stock Outperforming the S&P 500?"}, {"id":142431565,"url":"https://finnhub.io/api/news?id=bd97aef9c07a85a3b0403cde91733089cf1f386aa4a2a8a4ea3fdfb148209cae","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin","category":"company","datetime":1790384521,"headline":"Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan"}, {"id":142438323,"url":"https://finnhub.io/api/news?id=f64902b156e51968f8472d757adea49fd6dfd43ab176c85ace2d79c66f2e31e8","image":"","source":"Benzinga","related":"CRL","summary":"Deutsche Bank analyst Justin Bowers maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.","category":"company","datetime":1790339347,"headline":"Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320"}, {"id":142422937,"url":"https://finnhub.io/api/news?id=503eae205e8311b47407630a099d37c1ebc08fcac9e74631bad61f49ef982ae9","image":"","source":"Benzinga","related":"CRL","summary":"TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.","category":"company","datetime":1790331879,"headline":"TD Cowen Maintains Buy on Charles River, Raises Price Target to $325"}, {"id":142422938,"url":"https://finnhub.io/api/news?id=ea9efbffadd3510acdca4b68cee9fface3c802eb69248200128cada685ec337e","image":"","source":"Benzinga","related":"CRL","summary":"Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.","category":"company","datetime":1790331719,"headline":"Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330"}, {"id":142422939,"url":"https://finnhub.io/api/news?id=c09b9bf609cd928c8d605fc1713b96f1cbf5334546fe74fd61fb7948c451b729","image":"","source":"Benzinga","related":"CRL","summary":"RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.","category":"company","datetime":1790329577,"headline":"RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322"}, {"id":142422940,"url":"https://finnhub.io/api/news?id=93852949fe84b507c7dc838d6428a4e13e88285fa5fcf70009fcd7596169ffbe","image":"","source":"Benzinga","related":"CRL","summary":"Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.","category":"company","datetime":1790325141,"headline":"Barclays Maintains Overweight on Charles River, Raises Price Target to $330"}, {"id":142421440,"url":"https://finnhub.io/api/news?id=811cfc98c0f6098a703ed0ec518579d54e0410b864d8327c06e5f99fa9989ae3","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254790315/image_2254790315.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"CRL","summary":"Charles River Laboratories has doubled over the past year, outperforming despite regulatory and AI-related concerns. Click for this CRL stock update.","category":"company","datetime":1790325014,"headline":"Charles River Laboratories: Positive Investor Day Is Fully Priced In"}, {"id":142422941,"url":"https://finnhub.io/api/news?id=e5066d348aed8e386edd6c90545afbca1b3488663b992a52f45b3b7b00cf631c","image":"","source":"Benzinga","related":"CRL","summary":"Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.","category":"company","datetime":1790324119,"headline":"Mizuho Maintains Neutral on Charles River, Raises Price Target to $295"}, {"id":142422942,"url":"https://finnhub.io/api/news?id=9aede5f63a07646a47697cda4d6a9cc33dc8ca4ba5ec8eb1354c5334373c654a","image":"","source":"Benzinga","related":"CRL","summary":"Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.","category":"company","datetime":1790321165,"headline":"Baird Maintains Outperform on Charles River, Raises Price Target to $334"}, {"id":142414133,"url":"https://finnhub.io/api/news?id=f4295499197bd6a9de8d58c9c7c1374eb6f03327aba6b2783a0480cc9096195d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.","category":"company","datetime":1790320680,"headline":"CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?"}, {"id":142402006,"url":"https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...","category":"company","datetime":1790316582,"headline":"Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"}, {"id":142387947,"url":"https://finnhub.io/api/news?id=47b738c3783bc88c4221394848f31db0a9c7fff9a26d3d04bcfb555d444675b6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.","category":"company","datetime":1790291098,"headline":"Why Charles River Laboratories (CRL) Stock Is Up Today"}, {"id":142385317,"url":"https://finnhub.io/api/news?id=f6f2a26b9f5647288b5da04eda91284fe1679478b8b585e97013ed1ba637efe8","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.","category":"company","datetime":1790276701,"headline":"Discover which S&P500 stocks are making waves on Thursday."}, {"id":142384123,"url":"https://finnhub.io/api/news?id=dc1a57203f768e8c465d0c09732c290a21cef549361c1549da309d17b77fc56a","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.","category":"company","datetime":1790267701,"headline":"Explore the top gainers and losers within the S&P500 index in today's session."}, {"id":142385395,"url":"https://finnhub.io/api/news?id=6f5b2fba693b22fa73e8e6a1e1077de6b506ff84c3e4f65e588abdc05bf56df2","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"CRL","summary":"Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day September 24, 2026 9:00 AM EDTCompany ParticipantsTodd Spencer - Corporate Vice...","category":"company","datetime":1790263799,"headline":"Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript"}, {"id":142421668,"url":"https://finnhub.io/api/news?id=f659ca086a8fcedf0d0610b9b82a2c2c88705caf1d6794a316ed7f512bf7db64","image":"https://cdn.benzinga.com/files/images/story/2026/09/24/Strait-Of-Hormuz-Disruptions-Add-Pressur.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.","category":"company","datetime":1790256721,"headline":"S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today"}, {"id":142378283,"url":"https://finnhub.io/api/news?id=a8a984fffb4c90fac1ae5ea567d08372f13a17d94b853b64ecc24f97b900c9a9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Contract Research Organization Services Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Market research report provides strategic analysis of a sector projected to reach USD 87.43 billion in","category":"company","datetime":1790254860,"headline":"Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec"}, {"id":142380438,"url":"https://finnhub.io/api/news?id=a2ef362ffb079b4895e7b59dc86e83f637663f2a436f38c8296c0f31d591c263","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Opportunities include validated AI, cloud safety platforms, real-world evidence, integrated pharmacovigilance, patient-centric reporting and expansion in emerging markets.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Drug Safety Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. The global Drug Safety Market research report examines growth trends, regulatory developments, technology adoption, and regional pharmacovigilance priorities. The market is projected t","category":"company","datetime":1790254680,"headline":"Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & Parexel"}, {"id":142376964,"url":"https://finnhub.io/api/news?id=a09892f15cfc2342ebdbd7eccba7685a02e38f57612784a3706a8a6459b171a5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., September 24, 2026--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day","category":"company","datetime":1790251200,"headline":"Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day"}, {"id":142381619,"url":"https://finnhub.io/api/news?id=a166526344472844f31fa905ede32e817e5f4c62411d5fd86ba2c3facb599293","image":"https://cdn.benzinga.com/files/images/story/2026/09/24/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.","category":"company","datetime":1790244061,"headline":"Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday"}, {"id":142379184,"url":"https://finnhub.io/api/news?id=c9c3fd21de2cd9847355174c946ed9a05e8fef2bcfe94440baa4e75ebe390b60","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"CRL","summary":"2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.","category":"company","datetime":1790242663,"headline":"Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow"}, {"id":142383030,"url":"https://finnhub.io/api/news?id=5a23117f1282e193f88adcb943e6c75db8e2046cdfe9de402d6aeecba581c755","image":"","source":"Benzinga","related":"CRL","summary":"Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term financial targets","category":"company","datetime":1790237297,"headline":"Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%"}, {"id":142373385,"url":"https://finnhub.io/api/news?id=d48861e44962fa08c169889e4ad177ad893cd5c7d830c81b9ae4b7b19d9f66a3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Drug Discovery Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to","category":"company","datetime":1790236920,"headline":"Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave"}, {"id":142356198,"url":"https://finnhub.io/api/news?id=25104ceec68d66b64a1f37ae63ab3fec370b55efbfba320a48e272d2b62c2615","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Demand for outsourced pharmacokinetics services is rising, driven by AI, advanced bioanalysis, personalized medicine, biologics and complex global trials.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Pharmacokinetics Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Pharmacokinetics Services was estimated at US$853.5 Million in 2025 and is projected to reach US$1.4 Billion by 2032, growing at a CAGR of 7.8% from 2025 to 2032. Thi","category":"company","datetime":1790157300,"headline":"Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI"}, {"id":142356193,"url":"https://finnhub.io/api/news?id=311de3ed6a22059b7d90ce5ebc5e77b76db8162100a4e5f2ff486a2e18e71b21","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.","category":"company","datetime":1790156462,"headline":"3 Unpopular Stocks Walking a Fine Line"}, {"id":142356141,"url":"https://finnhub.io/api/news?id=a260791bca67346a94ec770a4d231c653e330840846dbd4be40d1641943f30ff","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Stricter safety rules, drug innovation and CRO outsourcing drive demand, while imaging, CRISPR and data analytics improve testing and reduce animal use.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"In Vivo Toxicology - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for In Vivo Toxicology was estimated at US$4.5 Billion in 2025 and is projected to reach US$6.0 Billion by 2032, growing at a CAGR of 4.3% from 2025 to 2032. This comprehensive re","category":"company","datetime":1790151000,"headline":"Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share"}, {"id":142356200,"url":"https://finnhub.io/api/news?id=4b7121759d1529c866f178de93b9efff8f881af028291fe6bdaa7da2428908cd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Drug Discovery Outsourcing - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Outsourcing was estimated at US$2.8 Billion in 2025 and is projected to reach US$4.5 Billion by 2032, growing at a CAGR","category":"company","datetime":1790150880,"headline":"Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market"}, {"id":142356201,"url":"https://finnhub.io/api/news?id=2d2bd2cab7ad130f538257142b21d0e7bc607f853a5295897c62739df0844c07","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Stricter safety rules and drug innovation are boosting demand, while high-throughput screening, predictive analytics, biomarkers, and non-animal methods create new opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Toxicology Testing Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Toxicology Testing Services was estimated at US$41.6 Billion in 2025 and is projected to reach US$59.8 Billion by 2032, growing at a CAGR of","category":"company","datetime":1790150760,"headline":"Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption"}, {"id":142340388,"url":"https://finnhub.io/api/news?id=f2b585db9bcaae9e84130e615a8e8ef41261f486b04f1b7c75b84e8417f50f6d","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.","category":"company","datetime":1790094901,"headline":"These S&P500 stocks are moving in today's session"}, {"id":142331584,"url":"https://finnhub.io/api/news?id=d33ece3ee562a4822bfaeaa446373e43f534cc74eba85ad447ffa3c152138c7e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Fragment-based Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Fragment-based Drug Discovery was valued at US$977 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of","category":"company","datetime":1790065920,"headline":"Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030"}, {"id":142331588,"url":"https://finnhub.io/api/news?id=ca0199f1023abdccb934011e5eeecbc6e27a4bede2603c32f0daa59bdad6d121","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Patient Derived Xenograft / PDX Models - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Patient Derived Xenograft / PDX Models was valued at US$467.5 Million in 2024 and is projected to reach US$1 Billion b","category":"company","datetime":1790065740,"headline":"Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI"}, {"id":142328488,"url":"https://finnhub.io/api/news?id=bc62eb43c32dce5bfd015e09762d0e8c734bea7afb5cfe2391be8b10ca2ca304","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Demand is rising for faster, accurate ADME-Tox testing, driven by complex biologics, tighter regulation, personalized medicine, and adoption of high-throughput, in vitro and in silico methods.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"ADME-Toxicology Testing - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for ADME-Toxicology Testing was valued at US$10 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR o","category":"company","datetime":1790065080,"headline":"Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption"}, {"id":142319439,"url":"https://finnhub.io/api/news?id=e74103a9743a075eb466d899fb135f9e669f504b3b882d1ade6c13cb524db239","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands […]","category":"company","datetime":1790044484,"headline":"Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter"}, {"id":142319440,"url":"https://finnhub.io/api/news?id=8f099109d81ba5b5c58bec5df08cfdf88fa63fe43fe21985b8aecadc1e0c3414","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"On September 8, Charles River Laboratories (NYSE:CRL) said its newly automated cartridge manufacturing suite for Endosafe endotoxin testing had reached full operational capacity in the third quarter, a milestone it had been building toward since the system went fully live in July. The timing matters. Charles River has spent much of 2026 shedding businesses and […]","category":"company","datetime":1790044183,"headline":"Charles River’s (CRL) New Automation Push Meets Old Margin Problems"}, {"id":142311611,"url":"https://finnhub.io/api/news?id=8c7135d0fa6090d4f7191c1c0d84f3470436760a453a710fda033133796434cf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Riverwater Partners, an investment management company, released its ‘Sustainable Value Strategy’ Q2 2026 investor letter. The letter can be downloaded here. Small-cap stocks achieved their best first-half performance since 1991, with the Russell 2500 Value Index rising 17%, driven by the technology sector. The Sustainable Value Strategy underperformed its benchmark in the second quarter. The shortfall […]","category":"company","datetime":1789993856,"headline":"Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL)"}

data_source finnhub_news_keyword_model

article_count 8

negative_hits 0

positive_hits 2

recomputed_at_score true

sentiment_score_raw 0.6

source_article_count 71

discarded_article_count 60

sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib

基本面 1.5 5/110 30% 1.5

資金流 14.8 20/110 74% 14.8

市場環境 6.4 15/110 42.67% 6.4

催化劑 2 20/110 10% 2

風險管理 6.3 10/110 63% 6.3

技術信號 22.9 30/110 76.33% 22.9

情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 15/50

ret_5d 0.0549

max_score 50

max_total 50

raw_total 15

vcp_bonus 0

vol_ratio 1.3077

ret_points 8

vol_points 4

range_ratio 1.058

volat_points 0

day_range_pct 0.043

model_version cursor_18_27_news_v2_160

available_bars 30

breakout_points 0

partial_history false

pullback_points 3

breakout_vol_bonus 0

first_breakout_20d false

return_window_days 5

first_breakout_bonus 0

breakout_quality_points 0

Risk management

level Elevated

reason risk management score >= 5/10

position

score 1.3

details

atrPct 4.1776

turnoverUsdM 401.3228

liquidityPoints 0.6

volatilityPoints 0.7

rrPoints 1.8

stopLevels

symbol US.CRL

rr_range 1:1.0-1:2.5

risk_profile 中等

stop_loss_price 289.0936

strength_details

ma_score 1.5

atr_score 1

rsi_score 3

macd_score 3

volume_score 2

market_adjustment 1

risk_reward_ratio 1.6

stop_loss_percent 8.4

take_profit_price 357.9717

target_multiplier 2.2

technical_strength 2.2

take_profit_percent 13.5

positionPoints 1.3

stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used

sector Health Care

concentratedSectorPenalty 0

riskRewardRatio 1.6158

stopLossPercent 8.3552

diversificationPoints 2

Calculation audit log

基本面分析總分: 1.5/5分
資金流分析總分: 14.8/20分
市場環境分析總分: 6.4/15分
催化劑分析: 2/20分
風險管理總分: 6.3/10分
技術信號分析總分: 22.9/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx

value 71.43

atr

atr 13.1782

rule ATR / current price; lower volatility scores higher

score 4

atr_pct 4.18

cci

rule Cursor_18.24 CCI bands

level 超買或超賣風險

score 2

value 153.76

cmf

rule Cursor_18.24 CMF bands

level 輕微流入

score 6

value 0.116

kdj

d 44.91

j 82.53

k 57.45

rule Cursor_18.24 K/D cross

score 4

signal 金叉

mfi

rule Cursor_18.24 MFI bands

level 平衡

score 6

value 58.31

obv

rule Cursor_18.24 recent_slope vs previous_slope

score 10

trend 強流入

value 1517923

recentSlope 125412.3

previousSlope -71940

rsi

value 62.7

sar

rule Cursor_18.24 Parabolic SAR

score 4

trend 下降

value 325.7015

position SAR喺價上

distancePct 3.25

previousTrend 下降

ma50

value 290.299

macd

macd 6.005

trend 強烈看漲

signal 5.5447

histogram 0.4603

vwap

rule Cursor_18.24 VWAP 20D consecutive close

score 10

value 298.4925

position 連續5日>VWAP

consecutiveAbove 19

volume

rule Cursor_18.24 volume ratio

level 有量

ratio 1.3

score 6

avgVolume 979656

currentVolume 1272223

derived

ma20 298.3875

ma50 290.299

prevClose 300.02

avgVolume10 871912

avgVolume20 979656

changePercent 5.14

avgVolumeForScore 979656

ma_cross

ma20 298.3875

ma50 290.299

rule Cursor_18.24 MA20/MA50 cross

cross 多頭

score 4

prevMa20 296.8705

prevMa50 289.53

spreadPct 2.79

isVolumeBreakout false

bollinger

lower 282.1502

upper 314.6248

position 上半部

rsi_short

value 71.43

macd_short

macd 0

trend 中性

signal 0

histogram 0

volume_ratio

ratio 1.3

Raw calculation JSON

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 4.177587440875338,
        "turnoverUsdM": 401.32275807223004,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 289.0936,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.6,
      "stop_loss_percent": 8.4,
      "take_profit_price": 357.9717,
      "target_multiplier": 2.2,
      "technical_strength": 2.2,
      "take_profit_percent": 13.5
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.6157651025936777,
    "stopLossPercent": 8.355174881750676,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 72.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 57.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 15
  },
  "market": {
    "ma20": 298.3875,
    "ma50": 290.299,
    "close": 315.45,
    "prevClose": 300.02,
    "avgVolume20": 979656,
    "volumeRatio": 1.3,
    "changePercent": 5.14
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 15,
    "details": {
      "ret_5d": 0.05494622969837648,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 15,
      "vcp_bonus": 0,
      "vol_ratio": 1.307660602322952,
      "ret_points": 8,
      "vol_points": 4,
      "range_ratio": 1.0580125767317416,
      "volat_points": 0,
      "day_range_pct": 0.04297032674051896,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 72.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 14.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 74,
        "contribution": 14.8
      },
      {
        "raw": 6.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 42.67,
        "contribution": 6.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 22.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 76.33,
        "contribution": 22.9
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 57.9,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 14.8/20分",
      "市場環境分析總分: 6.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 22.9/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.5,
      "資金流": 14.8,
      "市場環境": 6.4,
      "情緒分析": 4,
      "技術信號": 22.9,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 401.32275807223004,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.44
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 739.87200315,
                "ma50": 726.61519988,
                "name": "QQQ",
                "close": 717.63,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.61649505,
                "ma50": 768.28659516,
                "name": "SPY",
                "close": 769.049988,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 4.177587440875338,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142948227,
                "url": "https://finnhub.io/api/news?id=79f0a13d734af94e39735179cc832b22a1bdfab53f0be68fd4b4623bb8fef809",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.",
                "category": "company",
                "datetime": 1792163259,
                "headline": "Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers"
              },
              {
                "id": 142697487,
                "url": "https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PGNY vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791384004,
                "headline": "PGNY or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142592897,
                "url": "https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...",
                "category": "company",
                "datetime": 1790967988,
                "headline": "Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"
              },
              {
                "id": 142499581,
                "url": "https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]",
                "category": "company",
                "datetime": 1790698275,
                "headline": "Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"
              },
              {
                "id": 142402006,
                "url": "https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...",
                "category": "company",
                "datetime": 1790316582,
                "headline": "Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"
              },
              {
                "id": 142387947,
                "url": "https://finnhub.io/api/news?id=47b738c3783bc88c4221394848f31db0a9c7fff9a26d3d04bcfb555d444675b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.",
                "category": "company",
                "datetime": 1790291098,
                "headline": "Why Charles River Laboratories (CRL) Stock Is Up Today"
              },
              {
                "id": 142385395,
                "url": "https://finnhub.io/api/news?id=6f5b2fba693b22fa73e8e6a1e1077de6b506ff84c3e4f65e588abdc05bf56df2",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day September 24, 2026 9:00 AM EDTCompany ParticipantsTodd Spencer - Corporate Vice...",
                "category": "company",
                "datetime": 1790263799,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript"
              },
              {
                "id": 142379184,
                "url": "https://finnhub.io/api/news?id=c9c3fd21de2cd9847355174c946ed9a05e8fef2bcfe94440baa4e75ebe390b60",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.",
                "category": "company",
                "datetime": 1790242663,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow"
              }
            ],
            "raw_source": [
              {
                "id": 143031687,
                "url": "https://finnhub.io/api/news?id=9767c866ea027121f6e583a1c9d55c71caf1930dcf32f3011cf51a1089f09880",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "S&P 500 top movers today: Equifax and Hasbro gained over 10%, while General Motors and DaVita fell more than 7% in a mixed session.",
                "category": "company",
                "datetime": 1792523164,
                "headline": "S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall"
              },
              {
                "id": 143032118,
                "url": "https://finnhub.io/api/news?id=5706a549de19317028a89a3d0711c22462e81539f7468dfc667f38a79817cba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The S&P 500 Health Care Sector was on track to set a fresh closing high, leading Tuesday's broad market gains.",
                "category": "company",
                "datetime": 1792521676,
                "headline": "The Healthcare Sector Nears a New High. These Stocks Are Leading the Charge."
              },
              {
                "id": 143031680,
                "url": "https://finnhub.io/api/news?id=e11728fc8f5fa19627c71da56097d365124708caa38ac808ec39585063e67696",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "S&P 500 top movers for today's US session: Equifax led gainers at 11.46%, while General Motors led losers at -7.72%, ranked by percentage change.",
                "category": "company",
                "datetime": 1792514161,
                "headline": "S&P 500 Top Movers: Gainers and Losers From Today's US Session"
              },
              {
                "id": 143003297,
                "url": "https://finnhub.io/api/news?id=f1acfd41fd9b527a19736eca9f01d8234fd7f6f03163c95fadf8b26091f93997",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The global clinical trial management services market is projected to grow from $36.2 billion in 2025 to $68.4 billion by 2033, a new Research and Markets report finds, with North America holding 34.7%; high service costs and strict regulation remain hurdles for IQVIA, ICON, Medpace and Charles River Laboratories.Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- \"Clinical Trial Management Services Market Size, Share & Trends Analysis Report 2026-2033\" has been added to ResearchAndMarkets.com's offering.",
                "category": "company",
                "datetime": 1792404180,
                "headline": "Clinical Trial Management Services Market Size, Share, Trends, and Forecast, 2026-2033 | Drugmakers' Outsourcing Push Lifts Clinical Trial Management Toward $68 Billion"
              },
              {
                "id": 142948227,
                "url": "https://finnhub.io/api/news?id=79f0a13d734af94e39735179cc832b22a1bdfab53f0be68fd4b4623bb8fef809",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.",
                "category": "company",
                "datetime": 1792163259,
                "headline": "Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers"
              },
              {
                "id": 142944401,
                "url": "https://finnhub.io/api/news?id=5421d801a102802a5e484c0529471ffad3f61138737e42180b93aaa13d80796c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Moby summary of State Street Corporation's Q3 2026 earnings call",
                "category": "company",
                "datetime": 1792067400,
                "headline": "State Street Corporation Q3 2026 Earnings Call Summary"
              },
              {
                "id": 142918192,
                "url": "https://finnhub.io/api/news?id=ae660821716f3ea046ae6c39fc8c801e40c2138288b6e40e46dd199a41500235",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.15%. Currently, Charles River has a market capitalization of $15.44",
                "category": "company",
                "datetime": 1791978333,
                "headline": "Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Years"
              },
              {
                "id": 142881848,
                "url": "https://finnhub.io/api/news?id=d92b840d57c7cf26fe9122c59c96eb5effa81ac8761ad4ac4bb9f698ce01fff4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The partnership focuses on biologics quality control as well as viral and release testing under cGMP standards.",
                "category": "company",
                "datetime": 1791973542,
                "headline": "Charles River partners with Magellan Stem Cells on cell therapy"
              },
              {
                "id": 142872378,
                "url": "https://finnhub.io/api/news?id=62738761f42c073d33babe49d64f521c4f661034a6934bafccd6cd78abbca7c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Outsource clinical trials and leverage AI, decentralized models and regulatory expertise to cut costs, accelerate drug development and expand patient access.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- \"Healthcare Contract Research Organization (CRO) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. Global Healthcare Contract Research Organization (CRO) Market to Reach US$63.3 Billion by 2032 The global Healthcare Contract Research Organization (CRO) market, e",
                "category": "company",
                "datetime": 1791965460,
                "headline": "Healthcare Contract Research Organization (CRO) - Global Strategic Business Report: Secure Share of US$63.3 Billion Market by 2032 as IQVIA, ICON, Charles River, and Syneos Health Accelerate AI Trials"
              },
              {
                "id": 142882861,
                "url": "https://finnhub.io/api/news?id=93c15420dba820f73acdaf92c76e738f90d3f27ffc0b3533e13299a950b32e2a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Morgan Stanley  analyst Ricky Goldwasser   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.",
                "category": "company",
                "datetime": 1791894279,
                "headline": "Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340"
              },
              {
                "id": 142847677,
                "url": "https://finnhub.io/api/news?id=cddde621353a46d82cf197be60342f9be17dd2d28c88a4b6ef3b00fae32ed5d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., October 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r",
                "category": "company",
                "datetime": 1791892800,
                "headline": "Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development"
              },
              {
                "id": 142849184,
                "url": "https://finnhub.io/api/news?id=cae78aa67d83366e974f3475b844be12c4846a61277b95a025a3a90fd39e09b6",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical",
                "category": "company",
                "datetime": 1791878667,
                "headline": "Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions"
              },
              {
                "id": 142821923,
                "url": "https://finnhub.io/api/news?id=53efda3451be265502610e54f2aac7d0c18c98fe0810a2e8a51f996620eccbf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1791816423,
                "headline": "1 S&P 500 Stock to Target This Week and 2 We Question"
              },
              {
                "id": 142820380,
                "url": "https://finnhub.io/api/news?id=423149643bbad89b0db5f5911a4cddf6c995655e87d48181f8346bb1364ce1df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Boost ROI with AI-led design, automated high-throughput screening, customizable libraries, local production and diversified sourcing to cut costs and speed development.Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- \"Synthetic Antibody Library Global Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global synthetic antibody library market is experiencing rapid expansion, supported by rising demand for therapeutic antibodies, continued growth in biopharmaceutical research an",
                "category": "company",
                "datetime": 1791813600,
                "headline": "Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera"
              },
              {
                "id": 142760739,
                "url": "https://finnhub.io/api/news?id=9c7afb02e7e9d7abcc03d3cb0a983871d3e7356993eb8a452fb378da3b71b958",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., October 09, 2026--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call",
                "category": "company",
                "datetime": 1791547200,
                "headline": "Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call"
              },
              {
                "id": 142730419,
                "url": "https://finnhub.io/api/news?id=5741fde32d2d428cfb091510e2b9dc970e9a9cdc9798a0a9de13df26fb600389",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791477301,
                "headline": "Stay informed with the top movers within the S&P500 index on Thursday."
              },
              {
                "id": 142697487,
                "url": "https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PGNY vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791384004,
                "headline": "PGNY or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142695289,
                "url": "https://finnhub.io/api/news?id=6a5ab641dfa540f4273e0bc7343b63546d8bed6db48b9a05cc96fc59a2885f95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.",
                "category": "company",
                "datetime": 1791377460,
                "headline": "Charles River Gains 75.8% in a Year: What's Driving the Rally?"
              },
              {
                "id": 142665917,
                "url": "https://finnhub.io/api/news?id=96f2244ba53353df9f32cdb272b02c1bd237949d5c8d05b5b004c1bb61985f59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.",
                "category": "company",
                "datetime": 1791296940,
                "headline": "Is It Prudent to Add Teleflex Stock to Your Portfolio Now?"
              },
              {
                "id": 142663488,
                "url": "https://finnhub.io/api/news?id=442468620f7300edd97e96030827e9ed4020cc52e307d09ca48212ba3f770b1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass. & LONDON, October 06, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches",
                "category": "company",
                "datetime": 1791288000,
                "headline": "Charles River and Autolomous Partner to Transform Laboratory Execution Systems"
              },
              {
                "id": 142664252,
                "url": "https://finnhub.io/api/news?id=848f97ea160777aeb7ed35e35b75b28220a8868d46bf0b3145004ec3da03062c",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the launch of Apollo",
                "category": "company",
                "datetime": 1791274390,
                "headline": "Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration"
              },
              {
                "id": 142638288,
                "url": "https://finnhub.io/api/news?id=4796f000e83db0803c6b2ad30c002a2fc93fd2d01cc72622994706b14f78ea94",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791227101,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 142637485,
                "url": "https://finnhub.io/api/news?id=67961b010b1f3caecc8f221b133dc532a01b4d12e570aa9d8e37f37167ccb5a0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1791218101,
                "headline": "Which S&P500 stocks are moving on Monday?"
              },
              {
                "id": 142592897,
                "url": "https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...",
                "category": "company",
                "datetime": 1790967988,
                "headline": "Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"
              },
              {
                "id": 142577515,
                "url": "https://finnhub.io/api/news?id=4004dabfc4e71581127dd887539a0ecf3abbbdbfca0c74f5d1873ab9ad91f51b",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1790925229,
                "headline": "Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39"
              },
              {
                "id": 142518422,
                "url": "https://finnhub.io/api/news?id=4f000e219b76905d0e4602a2357c480f40a8a0d43c3dffe4cc108d40fa5b5d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- \"Animal Model - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp",
                "category": "company",
                "datetime": 1790774880,
                "headline": "Animal Model - Global Strategic Business Report:  Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory"
              },
              {
                "id": 142517531,
                "url": "https://finnhub.io/api/news?id=4bd4d48cb235fd301171991d0bfe3cb1a9387d7e335c5a84377e0aab6d16e21c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1790772002,
                "headline": "Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 142520420,
                "url": "https://finnhub.io/api/news?id=3bcdfc31b28a1e9d32bf937b1007a9d54474bac7dbab9269b99cd19feddf03cc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market capitalization of $15.15",
                "category": "company",
                "datetime": 1790766039,
                "headline": "Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 142520421,
                "url": "https://finnhub.io/api/news?id=cc0cb7255ec4f1bd0a5564f8462ab5a34a8f861a00590f3143b8ce54803c43bd",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "UBS  analyst Kevin Caliendo   reinstates Charles River (NYSE:CRL) with a Buy and announces $357 price target.",
                "category": "company",
                "datetime": 1790757739,
                "headline": "UBS Reinstates Buy on Charles River, Announces $357 Price Target"
              },
              {
                "id": 142499581,
                "url": "https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]",
                "category": "company",
                "datetime": 1790698275,
                "headline": "Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"
              },
              {
                "id": 142498448,
                "url": "https://finnhub.io/api/news?id=33d389ce10e1c3a470a93edeb6350bbdab2e11354e2d65d66fcec4c7016e4514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to",
                "category": "company",
                "datetime": 1790697120,
                "headline": "Pharmaceutical Impurity Synthesis and Isolation Services  Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River"
              },
              {
                "id": 142498449,
                "url": "https://finnhub.io/api/news?id=b4e488f22dcd680cd9d6f1073f1177520302265edfe111909503cd1374c8c6fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Computer-Aided Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound",
                "category": "company",
                "datetime": 1790697060,
                "headline": "Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth."
              },
              {
                "id": 142495085,
                "url": "https://finnhub.io/api/news?id=1f13747f30781afd5effdb4cfed035abc4e598b4fd9cf0d20bc8009c926b865a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:",
                "category": "company",
                "datetime": 1790681580,
                "headline": "NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs"
              },
              {
                "id": 142487027,
                "url": "https://finnhub.io/api/news?id=23e5453460dd9e1f12da1cd9842974b512e65d80948df3cb7bb3f7e48175af39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Boost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Experimental Animal Model Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experimental Animal Model Market, which is projected to reach USD 1.31 billion in 2026 and expand at a comp",
                "category": "company",
                "datetime": 1790669220,
                "headline": "Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, The Jackson Laboratory, Taconic Biosciences and Crown Bioscience Profiled"
              },
              {
                "id": 142467316,
                "url": "https://finnhub.io/api/news?id=da8b2e74678b76f253471de9bda93f56ad89236250cb85d9012c72196928a9af",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Jefferies  analyst David Windley   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.",
                "category": "company",
                "datetime": 1790589930,
                "headline": "Jefferies Maintains Buy on Charles River, Raises Price Target to $340"
              },
              {
                "id": 142452869,
                "url": "https://finnhub.io/api/news?id=da87991122131ba1bc51d2b82e98e0e933eff651c52951f9b03cee7151f06fa8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook.",
                "category": "company",
                "datetime": 1790542514,
                "headline": "Is Charles River Laboratories Stock Outperforming the S&P 500?"
              },
              {
                "id": 142431565,
                "url": "https://finnhub.io/api/news?id=bd97aef9c07a85a3b0403cde91733089cf1f386aa4a2a8a4ea3fdfb148209cae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin",
                "category": "company",
                "datetime": 1790384521,
                "headline": "Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan"
              },
              {
                "id": 142438323,
                "url": "https://finnhub.io/api/news?id=f64902b156e51968f8472d757adea49fd6dfd43ab176c85ace2d79c66f2e31e8",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Deutsche Bank  analyst Justin Bowers   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.",
                "category": "company",
                "datetime": 1790339347,
                "headline": "Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320"
              },
              {
                "id": 142422937,
                "url": "https://finnhub.io/api/news?id=503eae205e8311b47407630a099d37c1ebc08fcac9e74631bad61f49ef982ae9",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "TD Cowen  analyst Charles Rhyee   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.",
                "category": "company",
                "datetime": 1790331879,
                "headline": "TD Cowen Maintains Buy on Charles River, Raises Price Target to $325"
              },
              {
                "id": 142422938,
                "url": "https://finnhub.io/api/news?id=ea9efbffadd3510acdca4b68cee9fface3c802eb69248200128cada685ec337e",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Evercore ISI Group  analyst Ross Muken   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.",
                "category": "company",
                "datetime": 1790331719,
                "headline": "Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330"
              },
              {
                "id": 142422939,
                "url": "https://finnhub.io/api/news?id=c09b9bf609cd928c8d605fc1713b96f1cbf5334546fe74fd61fb7948c451b729",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "RBC Capital  analyst Ryan Halsted   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.",
                "category": "company",
                "datetime": 1790329577,
                "headline": "RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322"
              },
              {
                "id": 142422940,
                "url": "https://finnhub.io/api/news?id=93852949fe84b507c7dc838d6428a4e13e88285fa5fcf70009fcd7596169ffbe",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Barclays  analyst Luke Sergott   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.",
                "category": "company",
                "datetime": 1790325141,
                "headline": "Barclays Maintains Overweight on Charles River, Raises Price Target to $330"
              },
              {
                "id": 142421440,
                "url": "https://finnhub.io/api/news?id=811cfc98c0f6098a703ed0ec518579d54e0410b864d8327c06e5f99fa9989ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254790315/image_2254790315.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories has doubled over the past year, outperforming despite regulatory and AI-related concerns. Click for this CRL stock update.",
                "category": "company",
                "datetime": 1790325014,
                "headline": "Charles River Laboratories: Positive Investor Day Is Fully Priced In"
              },
              {
                "id": 142422941,
                "url": "https://finnhub.io/api/news?id=e5066d348aed8e386edd6c90545afbca1b3488663b992a52f45b3b7b00cf631c",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Mizuho  analyst Ann Hynes   maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.",
                "category": "company",
                "datetime": 1790324119,
                "headline": "Mizuho Maintains Neutral on Charles River, Raises Price Target to $295"
              },
              {
                "id": 142422942,
                "url": "https://finnhub.io/api/news?id=9aede5f63a07646a47697cda4d6a9cc33dc8ca4ba5ec8eb1354c5334373c654a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Baird  analyst Eric Coldwell   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.",
                "category": "company",
                "datetime": 1790321165,
                "headline": "Baird Maintains Outperform on Charles River, Raises Price Target to $334"
              },
              {
                "id": 142414133,
                "url": "https://finnhub.io/api/news?id=f4295499197bd6a9de8d58c9c7c1374eb6f03327aba6b2783a0480cc9096195d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "category": "company",
                "datetime": 1790320680,
                "headline": "CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?"
              },
              {
                "id": 142402006,
                "url": "https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...",
                "category": "company",
                "datetime": 1790316582,
                "headline": "Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"
              },
              {
                "id": 142387947,
                "url": "https://finnhub.io/api/news?id=47b738c3783bc88c4221394848f31db0a9c7fff9a26d3d04bcfb555d444675b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.",
                "category": "company",
                "datetime": 1790291098,
                "headline": "Why Charles River Laboratories (CRL) Stock Is Up Today"
              },
              {
                "id": 142385317,
                "url": "https://finnhub.io/api/news?id=f6f2a26b9f5647288b5da04eda91284fe1679478b8b585e97013ed1ba637efe8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1790276701,
                "headline": "Discover which S&P500 stocks are making waves on Thursday."
              },
              {
                "id": 142384123,
                "url": "https://finnhub.io/api/news?id=dc1a57203f768e8c465d0c09732c290a21cef549361c1549da309d17b77fc56a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1790267701,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 142385395,
                "url": "https://finnhub.io/api/news?id=6f5b2fba693b22fa73e8e6a1e1077de6b506ff84c3e4f65e588abdc05bf56df2",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day September 24, 2026 9:00 AM EDTCompany ParticipantsTodd Spencer - Corporate Vice...",
                "category": "company",
                "datetime": 1790263799,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript"
              },
              {
                "id": 142421668,
                "url": "https://finnhub.io/api/news?id=f659ca086a8fcedf0d0610b9b82a2c2c88705caf1d6794a316ed7f512bf7db64",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/24/Strait-Of-Hormuz-Disruptions-Add-Pressur.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.",
                "category": "company",
                "datetime": 1790256721,
                "headline": "S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today"
              },
              {
                "id": 142378283,
                "url": "https://finnhub.io/api/news?id=a8a984fffb4c90fac1ae5ea567d08372f13a17d94b853b64ecc24f97b900c9a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Contract Research Organization Services Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Market research report provides strategic analysis of a sector projected to reach USD 87.43 billion in",
                "category": "company",
                "datetime": 1790254860,
                "headline": "Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec"
              },
              {
                "id": 142380438,
                "url": "https://finnhub.io/api/news?id=a2ef362ffb079b4895e7b59dc86e83f637663f2a436f38c8296c0f31d591c263",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities include validated AI, cloud safety platforms, real-world evidence, integrated pharmacovigilance, patient-centric reporting and expansion in emerging markets.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Drug Safety Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. The global Drug Safety Market research report examines growth trends, regulatory developments, technology adoption, and regional pharmacovigilance priorities. The market is projected t",
                "category": "company",
                "datetime": 1790254680,
                "headline": "Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & Parexel"
              },
              {
                "id": 142376964,
                "url": "https://finnhub.io/api/news?id=a09892f15cfc2342ebdbd7eccba7685a02e38f57612784a3706a8a6459b171a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 24, 2026--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day",
                "category": "company",
                "datetime": 1790251200,
                "headline": "Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day"
              },
              {
                "id": 142381619,
                "url": "https://finnhub.io/api/news?id=a166526344472844f31fa905ede32e817e5f4c62411d5fd86ba2c3facb599293",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/24/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.",
                "category": "company",
                "datetime": 1790244061,
                "headline": "Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday"
              },
              {
                "id": 142379184,
                "url": "https://finnhub.io/api/news?id=c9c3fd21de2cd9847355174c946ed9a05e8fef2bcfe94440baa4e75ebe390b60",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.",
                "category": "company",
                "datetime": 1790242663,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow"
              },
              {
                "id": 142383030,
                "url": "https://finnhub.io/api/news?id=5a23117f1282e193f88adcb943e6c75db8e2046cdfe9de402d6aeecba581c755",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term financial targets",
                "category": "company",
                "datetime": 1790237297,
                "headline": "Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%"
              },
              {
                "id": 142373385,
                "url": "https://finnhub.io/api/news?id=d48861e44962fa08c169889e4ad177ad893cd5c7d830c81b9ae4b7b19d9f66a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Drug Discovery Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to",
                "category": "company",
                "datetime": 1790236920,
                "headline": "Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave"
              },
              {
                "id": 142356198,
                "url": "https://finnhub.io/api/news?id=25104ceec68d66b64a1f37ae63ab3fec370b55efbfba320a48e272d2b62c2615",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Demand for outsourced pharmacokinetics services is rising, driven by AI, advanced bioanalysis, personalized medicine, biologics and complex global trials.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Pharmacokinetics Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Pharmacokinetics Services was estimated at US$853.5 Million in 2025 and is projected to reach US$1.4 Billion by 2032, growing at a CAGR of 7.8% from 2025 to 2032. Thi",
                "category": "company",
                "datetime": 1790157300,
                "headline": "Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI"
              },
              {
                "id": 142356193,
                "url": "https://finnhub.io/api/news?id=311de3ed6a22059b7d90ce5ebc5e77b76db8162100a4e5f2ff486a2e18e71b21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
                "category": "company",
                "datetime": 1790156462,
                "headline": "3 Unpopular Stocks Walking a Fine Line"
              },
              {
                "id": 142356141,
                "url": "https://finnhub.io/api/news?id=a260791bca67346a94ec770a4d231c653e330840846dbd4be40d1641943f30ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Stricter safety rules, drug innovation and CRO outsourcing drive demand, while imaging, CRISPR and data analytics improve testing and reduce animal use.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"In Vivo Toxicology - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for In Vivo Toxicology was estimated at US$4.5 Billion in 2025 and is projected to reach US$6.0 Billion by 2032, growing at a CAGR of 4.3% from 2025 to 2032. This comprehensive re",
                "category": "company",
                "datetime": 1790151000,
                "headline": "Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share"
              },
              {
                "id": 142356200,
                "url": "https://finnhub.io/api/news?id=4b7121759d1529c866f178de93b9efff8f881af028291fe6bdaa7da2428908cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Drug Discovery Outsourcing - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Outsourcing was estimated at US$2.8 Billion in 2025 and is projected to reach US$4.5 Billion by 2032, growing at a CAGR",
                "category": "company",
                "datetime": 1790150880,
                "headline": "Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market"
              },
              {
                "id": 142356201,
                "url": "https://finnhub.io/api/news?id=2d2bd2cab7ad130f538257142b21d0e7bc607f853a5295897c62739df0844c07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Stricter safety rules and drug innovation are boosting demand, while high-throughput screening, predictive analytics, biomarkers, and non-animal methods create new opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Toxicology Testing Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Toxicology Testing Services was estimated at US$41.6 Billion in 2025 and is projected to reach US$59.8 Billion by 2032, growing at a CAGR of",
                "category": "company",
                "datetime": 1790150760,
                "headline": "Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption"
              },
              {
                "id": 142340388,
                "url": "https://finnhub.io/api/news?id=f2b585db9bcaae9e84130e615a8e8ef41261f486b04f1b7c75b84e8417f50f6d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1790094901,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 142331584,
                "url": "https://finnhub.io/api/news?id=d33ece3ee562a4822bfaeaa446373e43f534cc74eba85ad447ffa3c152138c7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Fragment-based Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Fragment-based Drug Discovery was valued at US$977 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of",
                "category": "company",
                "datetime": 1790065920,
                "headline": "Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030"
              },
              {
                "id": 142331588,
                "url": "https://finnhub.io/api/news?id=ca0199f1023abdccb934011e5eeecbc6e27a4bede2603c32f0daa59bdad6d121",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Patient Derived Xenograft / PDX Models - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Patient Derived Xenograft / PDX Models was valued at US$467.5 Million in 2024 and is projected to reach US$1 Billion b",
                "category": "company",
                "datetime": 1790065740,
                "headline": "Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI"
              },
              {
                "id": 142328488,
                "url": "https://finnhub.io/api/news?id=bc62eb43c32dce5bfd015e09762d0e8c734bea7afb5cfe2391be8b10ca2ca304",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Demand is rising for faster, accurate ADME-Tox testing, driven by complex biologics, tighter regulation, personalized medicine, and adoption of high-throughput, in vitro and in silico methods.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"ADME-Toxicology Testing - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for ADME-Toxicology Testing was valued at US$10 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR o",
                "category": "company",
                "datetime": 1790065080,
                "headline": "Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption"
              },
              {
                "id": 142319439,
                "url": "https://finnhub.io/api/news?id=e74103a9743a075eb466d899fb135f9e669f504b3b882d1ade6c13cb524db239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands […]",
                "category": "company",
                "datetime": 1790044484,
                "headline": "Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter"
              },
              {
                "id": 142319440,
                "url": "https://finnhub.io/api/news?id=8f099109d81ba5b5c58bec5df08cfdf88fa63fe43fe21985b8aecadc1e0c3414",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "On September 8, Charles River Laboratories (NYSE:CRL) said its newly automated cartridge manufacturing suite for Endosafe endotoxin testing had reached full operational capacity in the third quarter, a milestone it had been building toward since the system went fully live in July. The timing matters. Charles River has spent much of 2026 shedding businesses and […]",
                "category": "company",
                "datetime": 1790044183,
                "headline": "Charles River’s (CRL) New Automation Push Meets Old Margin Problems"
              },
              {
                "id": 142311611,
                "url": "https://finnhub.io/api/news?id=8c7135d0fa6090d4f7191c1c0d84f3470436760a453a710fda033133796434cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Riverwater Partners, an investment management company, released its ‘Sustainable Value Strategy’ Q2 2026 investor letter. The letter can be downloaded here. Small-cap stocks achieved their best first-half performance since 1991, with the Russell 2500 Value Index rising 17%, driven by the technology sector. The Sustainable Value Strategy underperformed its benchmark in the second quarter. The shortfall […]",
                "category": "company",
                "datetime": 1789993856,
                "headline": "Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL)"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 71,
            "discarded_article_count": 60
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.9,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(20.9%→14.2%)；跌縮量(近10日3日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 971203.3333333334,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 937000,
              "avg_vol_20": 972900,
              "avg_vol_30": 971203.3333333334,
              "range_pct_10": 0.14224123816004952,
              "range_pct_20": 0.17961635189043093,
              "range_pct_30": 0.20932001238484654,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9647825206530729,
              "dist_to_20d_high": 0.053555297136372436,
              "down_shrink_days": 3,
              "breakout_level_20d": 333.29999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6795396032106622
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 4.177587440875338,
              "turnoverUsdM": 401.32275807223004,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 289.0936,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.6,
            "stop_loss_percent": 8.4,
            "take_profit_price": 357.9717,
            "target_multiplier": 2.2,
            "technical_strength": 2.2,
            "take_profit_percent": 13.5
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.6157651025936777,
          "stopLossPercent": 8.355174881750676,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 13.1782,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 4.18
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 153.76
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.116
    },
    "kdj": {
      "d": 44.91,
      "j": 82.53,
      "k": 57.45,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 58.31
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 1517923,
      "recentSlope": 125412.3,
      "previousSlope": -71940
    },
    "rsi": 62.7,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 325.7015,
      "position": "SAR喺價上",
      "distancePct": 3.25,
      "previousTrend": "下降"
    },
    "ma50": 290.299,
    "macd": {
      "macd": 6.004996146174847,
      "trend": "強烈看漲",
      "signal": 5.544703514021795,
      "histogram": 0.4602926321530516
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 298.4925,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 19
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.3,
      "score": 6,
      "avgVolume": 979656,
      "currentVolume": 1272223
    },
    "derived": {
      "ma20": 298.3875,
      "ma50": 290.299,
      "prevClose": 300.02,
      "avgVolume10": 871912,
      "avgVolume20": 979656,
      "changePercent": 5.14,
      "avgVolumeForScore": 979656
    },
    "ma_cross": {
      "ma20": 298.3875,
      "ma50": 290.299,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 296.8705,
      "prevMa50": 289.53,
      "spreadPct": 2.79,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 282.1502,
      "upper": 314.6248,
      "position": "上半部"
    },
    "rsi_short": 71.43,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.3
    }
  }
}

Raw metrics JSON

{
  "close": 315.45,
  "volume": 1272223,
  "changePercent": 5.14
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.

US.CRL · Charles River Laboratories

觀望

Score and price trend

Summary

Rolling setup rating

Has the score quality changed?

Signals

Full calculation detail

Market inputs

Metrics snapshot

110-point main rating

基本面 — 1.5/5 · 較差

Sub-items

資金流 — 14.8/20 · 良好

Sub-items

institutional

details

warning

市場環境 — 6.4/15 · 較差

Sub-items

vix

details

trend

details

qqq

spy

催化劑 — 2/20 · 較差

Sub-items

catalyst

details

風險管理 — 6.3/10 · 一般

Sub-items

position

details

stopLevels

strength_details

diversification

details

技術信號 — 22.9/30 · 良好

Sub-items

vcpPayload

vcp_metrics

情緒分析 — 4/10 · 較差

Sub-items

sentiment

details

sentimentData

Dimension contribution

5D momentum v2 breakdown

Risk management

position

details

stopLevels

strength_details

diversification

details

Calculation audit log

Technical indicators

Raw calculation JSON

Raw metrics JSON